Equity Details
Price & Market Data
Price: $10.78
Daily Change: +$0.70 / 6.49%
Daily Range: $9.92 - $11.33
Market Cap: $528,560,448
Daily Volume: 1,024,356
Performance Metrics
1 Week: 11.06%
1 Month: 13.27%
3 Months: 15.71%
6 Months: -8.65%
1 Year: 28.48%
YTD: -28.89%
About REGENXBIO Inc. (RGNX)
Latest market trends for REGENXBIO Inc. (RGNX). The stock is priced at 10.78, showing a daily shift of +$0.70 / 6.49%. Market cap: 528,560,448. All performance data is provided for your review.
Company Details
Employees: 371
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.